...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Has the Time Arrived to Replace the Quick Prothrombin Time Test for Monitoring Oral Anticoagulant Therapy?
【24h】

Has the Time Arrived to Replace the Quick Prothrombin Time Test for Monitoring Oral Anticoagulant Therapy?

机译:是否有时间取代快速凝血酶原时间检测以监测口服抗凝治疗?

获取原文

摘要

The Quick (1) and Owren(2) prothrombin time (PT) tests remain the basis for monitoring anticoagulant therapy worldwide. The use of these tests is remarkable because the Quick PT preceded the discovery of the anticoagulant effect of dicoumarol in spoiled sweet clover and both tests were in use long before there was any understanding of the mechanism of the action of oral anticoagulants or which of the plasma factors were affected by them. Both PT tests are conceptually based on the four-factor theory of coagulation proposed by Morawitz in 1905 (3), and the two tests are similar. The reactions of the Quick PT test depend entirely on coagulation proteins present in the patient plasma sample; the Owren PT test adds components of bovine plasma to compensate for variability related to the coagulation proteins fibrinogen and factor V. Efforts to standardize the Quick PT have provided a common means for expressing patient PT results, the International Normalized Ratio (INR), and have provided a method for quantitative comparison of thromboplastin reagents (4). These efforts have improved interlaboratory comparability of mean values and standard deviations for groups of patient samples.In this issue of Clinical Chemistry , Horsti et al. (5) report PT results from testing the same samples, from patients receiving oral anticoagulants, on the same instruments but with different thromboplastins. They demonstrate that intrapatient comparability has not been achieved by use of the current standardization procedures (4). Their systematic comparison of seven different thromboplastins provides compelling evidence that neither the Quick nor the Owren PT test provides suitably comparable data for monitoring individual patients receiving oral anticoagulants if more than one thromboplastin reagent is used. Direct comparisons of the INR results from an individual patient’s samples measured with use of different thromboplastins indicate that the INR values can vary dramatically, certainly …
机译:快速(1)和Owren(2)凝血酶原时间(PT)测试仍然是全世界监测抗凝治疗的基础。这些测试的使用非常引人注目,因为Quick PT早于发现双香豆酚在变质甜三叶草中的抗凝作用之前,并且两项测试都在使用很久之前才了解口服抗凝剂的作用机理或血浆因素受到他们的影响。两种PT测试在概念上均基于Morawitz在1905年提出的凝血的四因素理论(3),并且两种测试相似。 Quick PT测试的反应完全取决于患者血浆样品中存在的凝结蛋白。 Owren PT试验添加了牛血浆成分以补偿与凝血蛋白纤维蛋白原和因子V相关的变异性。标准化Quick PT的努力提供了一种表达患者PT结果的通用方法,国际标准化比率(INR),并且提供了一种定量比较凝血活酶试剂的方法(4)。这些努力改善了实验室样本组平均值和标准偏差的实验室间可比性。 (5)报告了在相同的仪器上使用不同的凝血活酶测试相同样品,接受口服抗凝剂的患者的PT结果。他们证明,使用当前的标准化程序尚未实现患者内可比性(4)。他们对七种不同凝血活酶的系统比较提供了令人信服的证据,如果使用了多种凝血活酶试剂,Quick和Owren PT试验均无法提供适当的可比数据来监测接受口服抗凝剂的个别患者。通过使用不同的促凝血酶原蛋白对单个患者的样本进行的INR结果的直接比较表明,INR值可能会发生巨大变化,当然……

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号